Veterans Affairs Canada ends cannabis reimbursement for PTSD, chronic pain

Policy Change Eliminates Decade-Old Benefit

Veterans Affairs Canada terminated medical cannabis reimbursement effective immediately, forcing thousands of veterans to self-fund prescriptions that previously cost the department an estimated $75 million annually. The policy shift applies to all new authorizations and renewals issued after July 28, 2026, according to a departmental directive published on the Veterans Affairs Canada website. Veterans currently enrolled in the program will receive coverage through the end of their current authorization period, typically 90 to 180 days.

The department cited "evolving clinical evidence" and alignment with provincial health insurance frameworks as rationale for the change. No Canadian province currently covers medical cannabis under public drug plans.

6,200 Veterans Lose Coverage

Approximately 6,200 veterans enrolled in the cannabis reimbursement program will transition to out-of-pocket payment within six months. Established in 2008 following a Federal Court ruling, the program reimbursed up to 3 grams of dried cannabis daily at market rates ranging from $5 to $12 per gram depending on supplier and strain.

Average monthly out-of-pocket costs for veterans will range from $450 to $1,080 based on current dispensary pricing. That's a significant hit. Veterans with service-related disabilities rated at 100% will retain access to a $2,000 annual health benefits fund that can be applied toward cannabis, but the allocation must cover all non-covered health expenses including dental, vision, and mobility aids.

PTSD and Chronic Pain Primary Indications

Post-traumatic stress disorder and chronic pain account for 92% of medical cannabis authorizations among Canadian veterans, according to Veterans Affairs data published in the department's 2025 annual report. The remaining 8% include authorizations for insomnia, anxiety disorders, and neuropathic pain.

The policy reversal comes despite Veterans Affairs Canada's own 2024 research review concluding that cannabis showed moderate efficacy for PTSD symptom management in veteran populations, with adverse event rates comparable to first-line SSRIs.

No alternative pharmaceutical reimbursement expansion accompanied the cannabis coverage termination. Benzodiazepines, opioids, and SSRIs remain covered under the department's standard drug formulary.

Budget Pressure Drives Decision

Veterans Affairs Canada spent $74.8 million on cannabis reimbursement in fiscal year 2025, up from $42 million in 2023, according to departmental financial statements. The 78% two-year increase reflected both enrollment growth and per-gram price inflation as licensed producers shifted toward premium cultivars.

Officials project $18 million in annual savings from the policy change, funds that will be redirected to mental health counseling services and wait-time reduction initiatives. The 2026 federal budget allocated Veterans Affairs a 1.2% increase, well below the 3.1% inflation rate, creating pressure to contain pharmaceutical spending.

Advocacy Groups Threaten Legal Challenge

Veterans advocacy organizations including the Royal Canadian Legion and Veterans for Cannabis Access announced plans to explore legal action challenging the policy reversal. The groups argue that unilateral termination of an established benefit without consultation violates the Veterans Bill of Rights, a non-binding policy framework adopted in 2007.

Lawyers for the advocacy coalition are reviewing whether the policy change constitutes a breach of the Crown's fiduciary duty to veterans—the same legal theory that established the original cannabis reimbursement obligation in 2008. No formal legal filing has been submitted as of July 28.

Provincial Coverage Remains Unavailable

No Canadian province includes medical cannabis in public drug formularies, leaving veterans without alternative reimbursement pathways. Ontario's Trillium Drug Program, the most generous provincial catastrophic coverage plan, explicitly excludes cannabis and cannabis-derived products. Quebec, British Columbia, and Alberta maintain similar exclusions.

Private insurance coverage for medical cannabis remains rare. A 2025 survey by the Canadian Life and Health Insurance Association found that fewer than 8% of employer-sponsored health plans offered any cannabis reimbursement, typically capped at $500 to $1,500 annually. For complete context on veterans' access to cannabis benefits in Canada, see the CannIntel topic hub on Canada Veterans Cannabis Coverage.

The next test of the policy arrives in October 2026 when the first cohort of veterans exhaust their final authorized coverage period. Advocacy groups expect a spike in emergency room visits and crisis-line calls as veterans face sudden medication costs or discontinuation.